Literature DB >> 24122987

Therapy with siRNA for Vegf-c but not for Vegf-d suppresses wide-spectrum organ metastasis in an immunocompetent xenograft model of metastatic mammary cancer.

Masa-Aki Shibata1, Eiko Shibata, Junji Morimoto, Mariko Harada-Shiba.   

Abstract

Cancer metastasis contributes significantly to cancer mortality and is facilitated by lymphangiogenesis and angiogenesis. Vascular endothelial growth factors-C and D (VEGF-C and VEGF-D) are heavily involved in lymphangiogenesis. Using small interfering RNA (siRNA) against mouse Vegf-c, and Vegf-d, we sought to inhibit metastasis in a model of metastatic murine mammary cancer. BJMC3879Luc2 cell-induced mammary carcinomas received direct intratumoral injections in vivo of either plasmid VEGF-C/D siRNA (psiVEGF-C, psiVEGF-D) or a vector control followed by in vivo gene electrotransfer weekly for seven weeks. Treatment with psiVEGF-C and with psiVEGF-D resulted in lower tumor volumes as compared to the controls. Treatment with psiVEGF-C suppressed wide-spectrum organ metastasis involving lung and lymph nodes. Treatment with psiVEGF-C further reduced the number of dilated lymphatic vessels with invading cancer cells and inhibited tumor blood microvessel density. In contrast, although treatment with psiVEGF-D was not effective and gave equivocal results, it did induce some insignificant reduction in tumor volume increment, average numbers of lymph node metastases and average number of intratumoral dilated lymphatic vessels. In conclusion, specific silencing of the Vegf-c gene suppresses wide-spectrum organ metastasis, including the lung and lymph nodes. However, therapy with siRNA for Vegf-d was not adequately effective in this murine system.

Entities:  

Keywords:  VEGF-C; VEGF-D; mammary cancer; metastasis; siRNA

Mesh:

Substances:

Year:  2013        PMID: 24122987

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  [Changes of lymphatic vessel density in lung adenocarcinoma in situ, minimally invasive adenocarcinoma, and invasive adenocarcinoma and the regulatory factors].

Authors:  Ping He; Xia Gu; Xin Zeng; Yongmei Zheng; Xiaodong Lin
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-11-30

2.  A five generation family with a novel mutation in FOXC2 and lymphedema worsening to hydrops in the youngest generation.

Authors:  Carole Sargent; Julien Bauer; Muhamed Khalil; Parker Filmore; Michael Bernas; Marlys Witte; M Peggy Pearson; Robert P Erickson
Journal:  Am J Med Genet A       Date:  2014-09-22       Impact factor: 2.802

3.  Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis.

Authors:  Wang He; Guangzheng Zhong; Ning Jiang; Bo Wang; Xinxiang Fan; Changhao Chen; Xu Chen; Jian Huang; Tianxin Lin
Journal:  J Clin Invest       Date:  2018-01-22       Impact factor: 19.456

4.  CCR7 promote lymph node metastasis via regulating VEGF-C/D-R3 pathway in lung adenocarcinoma.

Authors:  Jie Yu; Shaolin Tao; Pingping Hu; Ruwen Wang; Chunshu Fang; Yi Xu; Di Qi; Zhuanqin Wei; Jingge Zhang; Qunyou Tan
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

5.  Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines.

Authors:  Erin Regan; Robert C Sibley; Bercin Kutluk Cenik; Asitha Silva; Luc Girard; John D Minna; Michael T Dellinger
Journal:  PLoS One       Date:  2016-03-07       Impact factor: 3.240

6.  Synthetic α-mangostin dilaurate strongly suppresses wide-spectrum organ metastasis in a mouse model of mammary cancer.

Authors:  Masa-Aki Shibata; Hitomi Hamaoka; Junji Morimoto; Tadashi Kanayama; Kentaro Maemura; Yuko Ito; Munekazu Iinuma; Yoichi Kondo
Journal:  Cancer Sci       Date:  2018-04-28       Impact factor: 6.716

7.  VEGFC/VEGFR3 axis mediates TGFβ1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cells.

Authors:  Lincan Duan; Lianhua Ye; Li Zhuang; Xiaolan Zou; Shan Liu; Yong Zhang; Lijuan Zhang; Congguo Jin; Yunchao Huang
Journal:  PLoS One       Date:  2018-07-11       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.